In the first half of 2026, biotech mergers and acquisitions reached $78 billion, significantly surpassing the total of $42 billion for all of 2025, fueled by several major deals over $5 billion. While strong factors like patent expirations and substantial cash reserves in large pharmaceutical companies support continued M&A activity, the pool of potential buyers is shrinking as top acquirers have exhausted much of their capacity. Companies such as Merck, Novo Nordisk, and AstraZeneca still possess significant resources, but future deal-making is expected to slow down, according to RBC Capital Markets.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://pluang.com/en/news-feed/ledakan-takeover-biotech-mulai-habis-pembeli
